Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20150313002
TCTR20150313002
Enrolling By Invitation
Phase 3

Intravenous N-acetyl-cysteine (NAC) Administration for Prevention of Post-embolization Syndrome in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Faculty of Medicine, Thammasat University0 sites80 target enrollmentMarch 13, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHepatocellular CarcinomaTransarterial Chemoembolization

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Hepatocellular Carcinoma
Sponsor
Faculty of Medicine, Thammasat University
Enrollment
80
Status
Enrolling By Invitation
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2015
End Date
December 31, 2015
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Faculty of Medicine, Thammasat University

Eligibility Criteria

Inclusion Criteria

  • •\- Patients with a diagnosis of hepatocellular carcinoma (HCC) and subjected to treat with chemoembolization (TACE) ( The diagnosis of HCC is based on (American association of liver diseases (AASLD) guidelines 2010\)
  • •\- Age 18\-65 years
  • •\- No contraindication to N\-acetyl\-cysteine

Exclusion Criteria

  • •\- Receiving other treatment within 6 months duration (e.g. radiofrequency ablation (RFA) or surgical liver resection)
  • •\- Having severe underlying illness e.g. ESRD, cardiac disease, AIDS, etc.
  • •\- Pregnancy or lactation
  • •\- Receiving possible drug interaction with NAC e.g. Nitroglycerine
  • •\- Denial to participate the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical Trialhearing impairmentHearing LossIntratympanic InjectionDexamethasoneAcetylcysteine
TCTR20160314003Student Research Committee114
Not yet recruiting
Phase 2
A clinical trial to study safety and efficacy of N-Acetylcysteine (NAC)(new drug) as an adjunct to standard treatment in patients with acute ischemic strokeHealth Condition 1: I633- Cerebral infarction due to thrombosis of cerebral arteries
CTRI/2019/05/019305AIIMS New Delhi
Recruiting
Phase 3
Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgeryRenal Impairment in cardiac surgeryRenal and Urogenital - Other renal and urogenital disordersCardiovascular - Other surgery
ACTRN12606000088549Prince of Wales Hospital200
Not yet recruiting
Not Applicable
AC for treatment of Obsessive-Compulsive DisorderObsessive-compulsive disorder.Obsessive-compulsive disorder
IRCT20170123032145N7Iran University of Medical Sciences44
Recruiting
Phase 1
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.Ototoxic Hearing Loss
NCT04291209Sunnybrook Health Sciences Centre80